The central point of interest was the display of the main directions used in the approach to the patient with pediatric MetS, starting from lifestyle changes and culminating with pharmacotherapy aimed at the various associated comorbidities - obesity, dyslipidemia, hypertension, changes in insulin metabolism or non-fatty liver -alcoholic. This evidence concerns the gene INS and Obesity.